Advanced

Increasing fecal butyrate in ulcerative colitis patients by diet. Controlled pilot study.

Hallert, C; Björck, Inger LU ; Nyman, Margareta LU ; Pousette, A; Grännö, Christer and Svensson, H (2003) In Inflammatory Bowel Diseases 9(2). p.116-121
Abstract
Summary: Topical butyrate has been shown to be effective in the treatment of ulcerative colitis (UC). Butyrate is derived from colonic fermentation of dietary fiber, and our aim was to study whether UC patients could safely increase the fecal butyrate level by dietary means. We enrolled 22 patients with quiescent UC (mean age, 44 years; 45% women; median time from last relapse, 1 year) in a controlled pilot trial lasting 3 months. The patients were instructed to add 60 g oat bran (corresponding to 20 g dietary fiber) to the daily diet, mainly as bread slices. Fecal short-chain fatty acids (SCFAs) including butyrate, disease activity, and gastrointestinal symptoms were recorded every 4 weeks. During the oat bran intervention the fecal... (More)
Summary: Topical butyrate has been shown to be effective in the treatment of ulcerative colitis (UC). Butyrate is derived from colonic fermentation of dietary fiber, and our aim was to study whether UC patients could safely increase the fecal butyrate level by dietary means. We enrolled 22 patients with quiescent UC (mean age, 44 years; 45% women; median time from last relapse, 1 year) in a controlled pilot trial lasting 3 months. The patients were instructed to add 60 g oat bran (corresponding to 20 g dietary fiber) to the daily diet, mainly as bread slices. Fecal short-chain fatty acids (SCFAs) including butyrate, disease activity, and gastrointestinal symptoms were recorded every 4 weeks. During the oat bran intervention the fecal butyrate concentration increased by 36% at 4 weeks (from 11 +/- 2 (mean +/- SEM) to 15 +/- 2 [mu]mol/g feces) (p < 0.01). The mean butyrate concentration over the entire test period was 14 +/- 1 [mu]mol/g feces (p < 0.05). Remaining fecal SCFA levels were unchanged. No patient showed signs of colitis relapse. Unlike controls, the patients showed no increase in gastrointestinal complaints during the trial. Yet patients reporting abdominal pain and reflux complaints at entry showed significant improvement at 12 weeks that returned to baseline 3 months later. This pilot study shows that patients with quiescent UC can safely take a diet rich in oat bran specifically to increase the fecal butyrate level. This may have clinical implications and warrants studies of the long-term benefits of using oat bran in the maintenance therapy in UC. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Inflammatory Bowel Diseases
volume
9
issue
2
pages
116 - 121
publisher
John Wiley & Sons
external identifiers
  • wos:000181468100005
  • pmid:12769445
  • scopus:0347926251
ISSN
1536-4844
DOI
10.1097/00054725-200303000-00005
language
English
LU publication?
yes
id
80e78788-c209-48ff-a9c0-f4547ceda347 (old id 127797)
date added to LUP
2007-07-18 08:40:03
date last changed
2018-10-21 03:29:21
@article{80e78788-c209-48ff-a9c0-f4547ceda347,
  abstract     = {Summary: Topical butyrate has been shown to be effective in the treatment of ulcerative colitis (UC). Butyrate is derived from colonic fermentation of dietary fiber, and our aim was to study whether UC patients could safely increase the fecal butyrate level by dietary means. We enrolled 22 patients with quiescent UC (mean age, 44 years; 45% women; median time from last relapse, 1 year) in a controlled pilot trial lasting 3 months. The patients were instructed to add 60 g oat bran (corresponding to 20 g dietary fiber) to the daily diet, mainly as bread slices. Fecal short-chain fatty acids (SCFAs) including butyrate, disease activity, and gastrointestinal symptoms were recorded every 4 weeks. During the oat bran intervention the fecal butyrate concentration increased by 36% at 4 weeks (from 11 +/- 2 (mean +/- SEM) to 15 +/- 2 [mu]mol/g feces) (p &lt; 0.01). The mean butyrate concentration over the entire test period was 14 +/- 1 [mu]mol/g feces (p &lt; 0.05). Remaining fecal SCFA levels were unchanged. No patient showed signs of colitis relapse. Unlike controls, the patients showed no increase in gastrointestinal complaints during the trial. Yet patients reporting abdominal pain and reflux complaints at entry showed significant improvement at 12 weeks that returned to baseline 3 months later. This pilot study shows that patients with quiescent UC can safely take a diet rich in oat bran specifically to increase the fecal butyrate level. This may have clinical implications and warrants studies of the long-term benefits of using oat bran in the maintenance therapy in UC.},
  author       = {Hallert, C and Björck, Inger and Nyman, Margareta and Pousette, A and Grännö, Christer and Svensson, H},
  issn         = {1536-4844},
  language     = {eng},
  number       = {2},
  pages        = {116--121},
  publisher    = {John Wiley & Sons},
  series       = {Inflammatory Bowel Diseases},
  title        = {Increasing fecal butyrate in ulcerative colitis patients by diet. Controlled pilot study.},
  url          = {http://dx.doi.org/10.1097/00054725-200303000-00005},
  volume       = {9},
  year         = {2003},
}